Safety Of Obinutuzumab Alone Or Combined With Chemotherapy In Previously Untreated (Fit Or Unfit) Or Relapsed/Refractory Chronic Lymphocytic Leukemia (Cll) Patients: Results From The Primary Analysis Of The Phase 3b Green Study

Introduction: Obinutuzumab (GA101; G) is a glycoengineered, type II anti-CD20 antibody with significant activity in CLL. GREEN (NCT01905943) is a non-randomized, open-label, single-arm, Phase 3b safety study of G alone or combined with chemotherapy (chemo) for previously untreated (1L) or relapsed/refractory (R/R) CLL patients (pts). Here, we report the primary objective (safety) of GREEN, which was carried out after all pts had a final response assessment or had withdrawn (data cut-off, Dec 29, 2016).